The OncoBEAM™ RAS CRC Platform provides proven clinical blood-based testing in your laboratory:

Our Test Menu

<table>
<thead>
<tr>
<th>KRAS 16</th>
<th>NRAS 18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 2: Codons 12 &amp; 13</td>
<td>Exon 2: Codons 12 &amp; 13</td>
</tr>
<tr>
<td>Exon 3: Codons 59 &amp; 61</td>
<td>Exon 3: Codons 59 &amp; 61</td>
</tr>
<tr>
<td>Exon 4: Codons 117 &amp; 146</td>
<td>Exon 4: Codons 117 &amp; 146</td>
</tr>
</tbody>
</table>

Bibliography


[6] OncoBEAM™ RAS CRC Kit Instructions for Use, OBMRASIVD.


OncoBEAM™ RAS CRC Platform

High Sensitivity – Proven Clinical Value

www.sysmex-europe.com/RAS

Go Beyond Biopsy with Blood

Not available in the USA
OncoBEAM™ RAS Platform Meets Current RAS Testing Guidelines

- In 2015, CRC clinical practice guidelines were updated to recommend expanded RAS testing prior to use of an anti-EGFR treatment.²,³,⁴
- A meta-analysis of nine randomized controlled trials was conducted on the prevalence of RAS mutations, for both KRAS Exon 2 and new KRAS and NRAS mutations, in metastatic colorectal cancer (mCRC). Patients with tumors exhibiting one of the new RAS mutations were found unlikely to significantly benefit from anti-EGFR monoclonal antibody therapy in mCRC.⁵
- The frequency of KRAS and NRAS mutations in Exons 2, 3 and 4 in the trials reviewed in the meta-analysis formed the basis for our OncoBEAM™ RAS CRC Kit. Using proven BEAMing technology, our platform offers a comprehensive panel of 34 mutations in the KRAS and NRAS oncogenes.

High Concordance with Tissue

Blood-based OncoBEAM™ RAS CRC Kit demonstrates high concordance with standard of care tissue testing.⁶

<table>
<thead>
<tr>
<th>OncoBEAM™ RAS CRC Plasma Result</th>
<th>Tissue RAS Result</th>
<th>Mutation Detected</th>
<th>No Mutation Detected</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation Detected</td>
<td>112</td>
<td>7</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>No Mutation Detected</td>
<td>9</td>
<td>110</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>121</td>
<td>117</td>
<td>238</td>
<td></td>
</tr>
</tbody>
</table>

- Overall Percent Agreement = 93.3% (222/238)
- Positive Percent Agreement = 92.6% (112/121)
- Negative Percent Agreement = 94.0% (110/117)
- OncoBEAM™ RAS CRC Stage IV Mutant Population = 50.0% (119/238)
- Tissue Stage IV Mutant Population = 50.8% (121/238)
High Sensitivity

The OncoBEAM™ RAS CRC Platform has the sensitivity required to detect low RAS percent mutant fractions in blood.

Equivalent Clinical Performance to Standard of Care Tissue Testing

No Significant Differences in Overall Survival Between Blood and Tissue Testing

OncoBEAM™ technology leverages the advantages of a minimally invasive blood-based test while retaining the accuracy of a tissue based test for selecting patients that will benefit most from anti-EGFR therapy.